Premium
Scandinavian clinical practice guideline on fluid and drug therapy in adults with acute respiratory distress syndrome
Author(s) -
Claesson J.,
Freundlich M.,
Gunnarsson I.,
Laake J. H.,
Møller M. H.,
Vandvik P. O.,
Varpula T.,
Aasmundstad T. A.
Publication year - 2016
Publication title -
acta anaesthesiologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.738
H-Index - 107
eISSN - 1399-6576
pISSN - 0001-5172
DOI - 10.1111/aas.12713
Subject(s) - medicine , ards , intensive care medicine , guideline , psychological intervention , evidence based practice , evidence based medicine , alternative medicine , psychiatry , pathology , lung
Background The objective of the Scandinavian Society of Anaesthesiology and Intensive Care Medicine ( SSAI ) task force on fluid and drug therapy in adults with acute respiratory distress syndrome ( ARDS ) was to provide clinically relevant, evidence‐based treatment recommendations according to standards for trustworthy guidelines. Methods The guideline was developed according to standards for trustworthy guidelines, including a systematic review of the literature and use of the GRADE methodology for assessment of the quality of evidence and for moving from evidence to recommendations. Results A total of seven ARDS interventions were assessed. We suggest fluid restriction in patients with ARDS (weak recommendation, moderate quality evidence). Also, we suggest early use of neuromuscular blocking agents ( NMBA s) in patients with severe ARDS (weak recommendation, moderate quality evidence). We recommend against the routine use of other drugs, including corticosteroids, beta2 agonists, statins, and inhaled nitric oxide ( iNO ) or prostanoids in adults with ARDS (strong recommendations: low‐ to high‐quality evidence). These recommendations do not preclude the use of any drug or combination of drugs targeting underlying or co‐existing disorders. Conclusion This guideline emphasizes the paucity of evidence of benefit – and potential for harm – of common interventions in adults with ARDS and highlights the need for prudence when considering use of non‐licensed interventions in this patient population.